This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Matsuyama, H. Articles by Bergerheim, U. S. R. Search for Related Content PubMed PubMed Citation Articles by Matsuyama, H. Articles by Bergerheim, U. S. R.

p53 Deletion as a Genetic Marker in Urothelial Tumor by Fluorescence in Situ Hybridization¹

Departments of Urology [H. M., P. E., U. B.], Pathology [T. H., G. A.], and Medical Radiobiology [Y. P., B. T.], Karolinska Hospital, 171 76 Stockholm, Sweden; Departments of Urology [P-U. M.] and Pathology [E. M., C. B.], University of Uppsala, 751 85 Uppsala, Sweden; Department of Biochemistry, Royal Institute of Technology, Stockholm, Sweden [A. H., M. U.]; Deutsches Krebsforschungzentrum, Heidelberg, Germany [P. L.]; and Department of Urology, Yamaguchi University School of Medicine, Ube, 755 Japan [K. N.]

In order to investigate the significance of p53 deletion, 42 specimens of transitional cell carcinoma were analyzed by interphase cytogenetics with a fluorescence in situ hybridization technique and compared with clinicopathological and cytochemical parameters. In total, 27 (64%) and 16 (38%) specimens demonstrated p53 deletion and overexpression, respectively. The p53 deletion was significantly correlated with grade (P < 0.01), stage (P < 0.05), S-phase fraction (P < 0.05), and DNA ploidy (P < 0.01), while p53 overexpression correlated only with grade (P < 0.05). The close correlation of p53 deletion with clinicopathological parameters suggests p53 deletion to be of clinical importance to indicate the malignant potential of human urothelial tumors.

¹ Supported by grants from the Swedish Cancer Society (Grant 1192/B90/01X), The Swedish Society of Medicine, funds from the Karolinska Institute, the Swedish Cancer Foundation, and the Scandinavia-Japan Sasakawa Foundation.

² To whom requests for reprints should be addressed.

Received 7/25/94. Accepted 10/20/94.